[PDF][PDF] Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer

A Alam, E Levanduski, P Denz, HS Villavicencio… - Cancer cell, 2022 - cell.com
A Alam, E Levanduski, P Denz, HS Villavicencio, M Bhatta, L Alhorebi, Y Zhang, EC Gomez…
Cancer cell, 2022cell.com
TH 2 cells and innate lymphoid cells 2 (ILC2) can stimulate tumor growth by secreting pro-
tumorigenic cytokines such as interleukin-4 (IL-4), IL-5, and IL-13. However, the
mechanisms by which type 2 immune cells traffic to the tumor microenvironment are
unknown. Here, we show that oncogenic Kras G12D increases IL-33 expression in
pancreatic ductal adenocarcinoma (PDAC) cells, which recruits and activates TH 2 and ILC2
cells. Correspondingly, cancer-cell-specific deletion of IL-33 reduces TH 2 and ILC2 …
Summary
TH2 cells and innate lymphoid cells 2 (ILC2) can stimulate tumor growth by secreting pro-tumorigenic cytokines such as interleukin-4 (IL-4), IL-5, and IL-13. However, the mechanisms by which type 2 immune cells traffic to the tumor microenvironment are unknown. Here, we show that oncogenic KrasG12D increases IL-33 expression in pancreatic ductal adenocarcinoma (PDAC) cells, which recruits and activates TH2 and ILC2 cells. Correspondingly, cancer-cell-specific deletion of IL-33 reduces TH2 and ILC2 recruitment and promotes tumor regression. Unexpectedly, IL-33 secretion is dependent on the intratumoral fungal mycobiome. Genetic deletion of IL-33 or anti-fungal treatment decreases TH2 and ILC2 infiltration and increases survival. Consistently, high IL-33 expression is observed in approximately 20% of human PDAC, and expression is mainly restricted to cancer cells. These data expand our knowledge of the mechanisms driving PDAC tumor progression and identify therapeutically targetable pathways involving intratumoral mycobiome-driven secretion of IL-33.
cell.com